Clinical trial · Interventional
Oral Propranolol Versus Fractional Carbon Dioxide CO2 Laser Assisted Delivery of Topical Timolol for Treatment of Infantile Hemangioma
Oral Propranolol Versus Fractional Carbon Dioxide CO2 Laser Assisted Delivery of Topical Timolol for Treatment of Infantile Hemangioma; A Randomized Controlled Comparative Study
NCT07560332CI-TRIAL-00110153completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess and compare the efficacy of systemic beta-blocker therapy with the efficacy and safety of fractional carbon dioxide laser-assisted delivery of a topical beta-blocker solution in the treatment of infantile hemangioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infantile Hemangioma (IH) | Infantile Hemangioma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fractional CO2 laser with topical timolol | Device | — | UNRESOLVED |
| Propranolol 1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Propranolol
- description
- oral propranolol group for treatment of infantile hemangioma
- interventionNames
- Drug: Propranolol 1
- type
- EXPERIMENTAL
- label
- Topical timolol with fractional CO2 laser treatment of infantile hemangioma
- description
- weekly session of fractional CO2 laser with topical timolol application
- interventionNames
- Device: Fractional CO2 laser with topical timolol
Primary outcomes (1)
- measure
- Improvement of global assessment score of infantile hemangioma
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Month
- Maximum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: , aged 1 month to 12 years \- presenting with superficial, deep, mixed, or proliferating IH. Exclusion Criteria: * other cutaneous or systemic infections * chronic systemic diseases * known allergy to topical timolol maleate * contraindications to laser or beta-blocker therapy * IH involving mucosal or perimucosal sites * and a history of adverse reactions to laser therapy or keloid tendency.
References
Publications (0)
Data not yet available
No reference posted for this study.